DNLI News and Press, Denali Therapeutics Inc. From 07/26/21

Shares of Denali Therapeutics (NASDAQ: DNLI) had sunk 11.2% as of 12:02 p.m. EDT on Monday. The decline came after the company presented interim results on Sunday from a phase 1/2 study evaluating experimental enzyme replacement therapy DNL310 in treating the rare neurodegenerative ...

Denali Therapeutics (DNLI) announces additional positive interim data from Phase 1/2 study evaluating ETV:IDS (DNL310) for the treatment of both central nervous system ((CNS)) and peripheral manifestations of Hunter syndrome (MPS II).All patients received weekly intravenous doses of DNL310 af...

Rapid reduction and sustained normalization of heparan sulfate in CSF demonstrated robust and durable CNS activity with intravenous administration, and enhanced peripheral activity with reductions in urine and serum heparan sulfate after switching from standard-of-care idursulfase ...

Biotech stocks had a muted first half with the S&P Biotech Index down year-to-date, and more than 20% lower from its mid-February peak. The decline in biotech stocks coincided with a spike in interest rates and stabilizing interest rates can provide a boost to valuations. M&am...

SOUTH SAN FRANCISCO, Calif., July 15, 2021 (GLOBE NEWSWIRE) -- Denali Therapeutics Inc. (NASDAQ: DNLI), a biopharmaceutical company developing a broad portfolio of product candidates engineered to cross the blood-brain barrier (BBB) for neurodegenerative diseases, today announced its partic...

SOUTH SAN FRANCISCO, Calif., June 28, 2021 (GLOBE NEWSWIRE) -- Denali Therapeutics Inc. (NASDAQ: DNLI), a biopharmaceutical company developing a broad portfolio of product candidates engineered to cross the blood-brain barrier (BBB) for neurodegenerative diseases, today announced that i...

Chip Somodevilla/Getty Images News Stephen Hahn, an oncologist who served as FDA commissioner as the Trump administration dealt with the COVID-19 pandemic, has joined venture capital firm Flagship Pioneering as a chief medical officer. Hahn will lead Flagship's Preemptive Medicine and Health ...

Dr. Stephen Hahn, 24th US FDA Commissioner and Former Chief Medical Executive at MD Anderson, joins Flagship Pioneering as Chief Medical Officer of Flagship's Preemptive Medicine and Health Security Initiative PR Newswire CAMBRIDGE, Mass. , June 14, 2021 /PRNewsw...

The following slide deck was published by Denali Therapeutics Inc. in conjunction with this event. For further details see: Denali Therapeutics (DNLI) Presents At Goldman Sachs 42nd Annual Global Healthcare Conference - Slideshow

Biotechs are ready to march forcefully higher after a lengthy consolidation. Approval of Biogen's Alzheimer's treatment creates a bonanza for neurodegenerative-focused companies and the overall biotech sector. The lower bar set for approval poses risk for Biogen in the out years. ...